iBio (IBIO) Change in Net Loans (2024 - 2025)

iBio (IBIO) posted quarterly Change in Net Loans of $46000.0 for Q2 2025, up 4700.0% quarter-over-quarter from -$1000.0 in Q4 2024.

iBio (IBIO) Change in Net Loans (2024 - 2025) Analysis & Trends

iBio (IBIO) has reported Change in Net Loans for 2 consecutive years, with $46000.0 the latest figure, recorded in Q2 2025.

In Q2 2025, Change in Net Loans changed N/A year-over-year to $46000.0; the TTM figure through Jun 2025 stood at $758000.0 (changed N/A YoY), while the FY2025 annual figure was $758000.0, changed N/A from the prior year.
Change in Net Loans grew to $46000.0 in Q2 2025 per IBIO's latest filing, from -$1000.0 in the prior quarter.
Across five years, Change in Net Loans topped out at $713000.0 in Q3 2024 and bottomed at -$1000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Net Loans (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	iBio	172.22 Mn	172.22 Mn	-	-

Download Data